Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19)

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19). / Moestrup, Kasper S; Reekie, Joanne; Zucco, Adrian G; Jensen, Tomas Ø; Jensen, Jens-Ulrik S; Wiese, Lothar; Ostrowski, Sisse R; Niemann, Carsten U; MacPherson, Cameron Ross; Lundgren, Jens; Helleberg, Marie.

In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, No. 3, 08.02.2023, p. e82-e89.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Moestrup, KS, Reekie, J, Zucco, AG, Jensen, TØ, Jensen, J-US, Wiese, L, Ostrowski, SR, Niemann, CU, MacPherson, CR, Lundgren, J & Helleberg, M 2023, 'Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19)', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 76, no. 3, pp. e82-e89. https://doi.org/10.1093/cid/ciac639

APA

Moestrup, K. S., Reekie, J., Zucco, A. G., Jensen, T. Ø., Jensen, J-U. S., Wiese, L., Ostrowski, S. R., Niemann, C. U., MacPherson, C. R., Lundgren, J., & Helleberg, M. (2023). Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3), e82-e89. https://doi.org/10.1093/cid/ciac639

Vancouver

Moestrup KS, Reekie J, Zucco AG, Jensen TØ, Jensen J-US, Wiese L et al. Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 Feb 8;76(3):e82-e89. https://doi.org/10.1093/cid/ciac639

Author

Moestrup, Kasper S ; Reekie, Joanne ; Zucco, Adrian G ; Jensen, Tomas Ø ; Jensen, Jens-Ulrik S ; Wiese, Lothar ; Ostrowski, Sisse R ; Niemann, Carsten U ; MacPherson, Cameron Ross ; Lundgren, Jens ; Helleberg, Marie. / Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19). In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 ; Vol. 76, No. 3. pp. e82-e89.

Bibtex

@article{8eeb79f972594e13a50716566481177c,

title = "Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19)",

abstract = "BACKGROUND: Many interventional in-patient coronavirus disease 2019 (COVID-19) trials assess primary outcomes through day 28 post-randomization. Since a proportion of patients experience protracted disease or relapse, such follow-up period may not fully capture the course of the disease, even when randomization occurs a few days after hospitalization.METHODS: Among adults hospitalized with COVID-19 in eastern Denmark from 18 March 2020-12 January 2021 we assessed all-cause mortality, recovery, and sustained recovery 90 days after admission, and readmission and all-cause mortality 90 days after discharge. Recovery was defined as hospital discharge and sustained recovery as recovery and alive without readmissions for 14 consecutive days.RESULTS: Among 3386 patients included in the study, 2796 (82.6%) reached recovery and 2600 (77.0%) achieved sustained recovery. Of those discharged from hospital, 556 (19.9%) were readmitted and 289 (10.3%) died. Overall, the median time to recovery was 6 days (interquartile range [IQR]: 3-10), and 19 days (IQR: 11-33) among patients in intensive care in the first 2 days of admission.CONCLUSIONS: Postdischarge readmission and mortality rates were substantial. Therefore, sustained recovery should be favored to recovery outcomes in clinical COVID-19 trials. A 28-day follow-up period may be too short for the critically ill.",

keywords = "Adult, Humans, COVID-19, Patient Readmission, Patient Discharge, Aftercare, SARS-CoV-2, Hospitalization, Hospitals, Hospital Mortality",

author = "Moestrup, {Kasper S} and Joanne Reekie and Zucco, {Adrian G} and Jensen, {Tomas {\O}} and Jensen, {Jens-Ulrik S} and Lothar Wiese and Ostrowski, {Sisse R} and Niemann, {Carsten U} and MacPherson, {Cameron Ross} and Jens Lundgren and Marie Helleberg",

note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",

year = "2023",

month = feb,

day = "8",

doi = "10.1093/cid/ciac639",

language = "English",

volume = "76",

pages = "e82--e89",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

RIS

TY - JOUR

T1 - Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19)

AU - Moestrup, Kasper S

AU - Reekie, Joanne

AU - Zucco, Adrian G

AU - Jensen, Tomas Ø

AU - Jensen, Jens-Ulrik S

AU - Wiese, Lothar

AU - Ostrowski, Sisse R

AU - Niemann, Carsten U

AU - MacPherson, Cameron Ross

AU - Lundgren, Jens

AU - Helleberg, Marie

PY - 2023/2/8

Y1 - 2023/2/8

N2 - BACKGROUND: Many interventional in-patient coronavirus disease 2019 (COVID-19) trials assess primary outcomes through day 28 post-randomization. Since a proportion of patients experience protracted disease or relapse, such follow-up period may not fully capture the course of the disease, even when randomization occurs a few days after hospitalization.METHODS: Among adults hospitalized with COVID-19 in eastern Denmark from 18 March 2020-12 January 2021 we assessed all-cause mortality, recovery, and sustained recovery 90 days after admission, and readmission and all-cause mortality 90 days after discharge. Recovery was defined as hospital discharge and sustained recovery as recovery and alive without readmissions for 14 consecutive days.RESULTS: Among 3386 patients included in the study, 2796 (82.6%) reached recovery and 2600 (77.0%) achieved sustained recovery. Of those discharged from hospital, 556 (19.9%) were readmitted and 289 (10.3%) died. Overall, the median time to recovery was 6 days (interquartile range [IQR]: 3-10), and 19 days (IQR: 11-33) among patients in intensive care in the first 2 days of admission.CONCLUSIONS: Postdischarge readmission and mortality rates were substantial. Therefore, sustained recovery should be favored to recovery outcomes in clinical COVID-19 trials. A 28-day follow-up period may be too short for the critically ill.

AB - BACKGROUND: Many interventional in-patient coronavirus disease 2019 (COVID-19) trials assess primary outcomes through day 28 post-randomization. Since a proportion of patients experience protracted disease or relapse, such follow-up period may not fully capture the course of the disease, even when randomization occurs a few days after hospitalization.METHODS: Among adults hospitalized with COVID-19 in eastern Denmark from 18 March 2020-12 January 2021 we assessed all-cause mortality, recovery, and sustained recovery 90 days after admission, and readmission and all-cause mortality 90 days after discharge. Recovery was defined as hospital discharge and sustained recovery as recovery and alive without readmissions for 14 consecutive days.RESULTS: Among 3386 patients included in the study, 2796 (82.6%) reached recovery and 2600 (77.0%) achieved sustained recovery. Of those discharged from hospital, 556 (19.9%) were readmitted and 289 (10.3%) died. Overall, the median time to recovery was 6 days (interquartile range [IQR]: 3-10), and 19 days (IQR: 11-33) among patients in intensive care in the first 2 days of admission.CONCLUSIONS: Postdischarge readmission and mortality rates were substantial. Therefore, sustained recovery should be favored to recovery outcomes in clinical COVID-19 trials. A 28-day follow-up period may be too short for the critically ill.

KW - Adult

KW - Humans

KW - COVID-19

KW - Patient Readmission

KW - Patient Discharge

KW - Aftercare

KW - SARS-CoV-2

KW - Hospitalization

KW - Hospitals

KW - Hospital Mortality

U2 - 10.1093/cid/ciac639

DO - 10.1093/cid/ciac639

M3 - Journal article

C2 - 35938291

VL - 76

SP - e82-e89

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -

ID: 358551192